FindTrial
Sign In

Evaluation of safety and efficacy of Telpegfilgrastim (long-acting) in patients with decrease ovarian reserve (DOR): a multicenter, randomized controlled clinical trial

Evaluation of safety and efficacy of Telpegfilgrastim (long-acting) in patients with decrease ovarian reserve (DOR): a multicenter, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091521
Enrollment
Unknown
Registered
2024-10-30
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decrease ovarian reserve (DOR)

Interventions

Intervention group :Elpegfilgrastim (long-acting)
Control group :Placebo

Sponsors

The Second Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Willingness to participate in the study and provide written informed consent; 2) Having undergone IVF/ICSI cycles; 3) Diagnosis of POR defined as matching one of the following conditions: (1) AMH <= 2.0 ng/mL, (2) 10 IU/L <= bFSH <= 20 IU/L and (3) antral follicles <= 7; 4) Aged 20–40 years; 5) Ovulation induction by progestin-primed ovarian stimulation protocol (PPOS);

Exclusion criteria

Exclusion criteria: 1) Contraindications to IVF/ICSI treatment; 2) Patients with high and normal ovarian reserves; 3) Contraindications to didroxerone, uterine progesterone and G-CSF.

Design outcomes

Primary

MeasureTime frame
The number of ova obtained;Number of high-quality embryos on D3;—

Secondary

MeasureTime frame
MII oocyte number;Transferable embryos rate;—

Countries

China

Contacts

Public ContactFang Wang

The Second Hospital of Lanzhou University

ery_fwang@lzu.edu.cn+86 139 1930 2888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026